CDIB BioScience Venture Management

Investment decisions are made by a dedicated life sciences investment team in San Diego, supported by CDIB Capital Group's broader cross-Pacific platform. The team combines scientific PhDs and former medtech operators with financial professionals who have execution experience across US and Asian healthcare markets. Specific named principals at the fund level have not been widely disclosed in public records.

The firm sources deal flow through deep academic and clinical networks within the San Diego and broader California life sciences ecosystems, supplemented by CDIB Capital Group's corporate and manufacturing relationships in Asia. Its cross-Pacific architecture gives it early visibility into US startups preparing for Asian regulatory submissions or manufacturing scale-ups — a sourcing channel that generalist US venture funds typically lack. The firm also syndicates with top-tier early-stage biotech VCs for co-investment rights.

It functions as a dedicated sector platform backed by permanent capital from CDIB Capital Group, the international investment subsidiary of China Development Industrial Bank. It is not a typical limited-partner venture fund that must raise from external LPs on a cycle, but it also operates with more investment committee independence and sector specialization than a conventional corporate venture capital unit. This structure gives the firm flexibility to hold positions longer and support portfolio companies through regulatory and manufacturing milestones.

The firm engages primarily in direct venture and growth equity deals but maintains relationships with top-tier US biotech venture funds for co-investment and syndication purposes. Its investment posture allows for both lead and follow participation, with a preference for securing board observer or governance rights when portfolio companies plan Asian market entry. No public records indicate a significant fund-of-funds allocation within the dedicated bioscience vehicle.

The firm invests from seed and start-up through expansion and late-stage rounds, per Altss research. Early-stage therapeutics and diagnostics platforms form the core of its portfolio, with later-stage participation reserved for companies nearing regulatory milestones or preparing for Asian commercial launches. The permanent capital structure permits the firm to remain active across follow-on rounds without the reserve-allocation constraints typical of blind-pool venture funds.

CDIB BioScience Venture Management is the dedicated life sciences venture platform within CDIB Capital Group, which is the global private equity and alternative asset management arm of China Development Industrial Bank. CDIB Capital Group invests across private equity, real estate, credit, and healthcare globally, with the San Diego-based bioscience team executing the group's specialized life sciences mandate. The parent entity provides permanent capital, cross-Pacific operational support, and relationships with Asian regulators and manufacturers.

The firm's San Diego headquarters places it inside one of the world's highest-density biotechnology research clusters, while its affiliation with CDIB Capital Group provides direct lines to Asian regulatory agencies like Taiwan's TFDA and manufacturing partners across the semiconductor-adjacent medtech supply chain. This dual footprint allows portfolio companies to run US clinical development and Asian manufacturing scale-up simultaneously — a structural advantage that standalone US or European healthcare funds cannot replicate without building their own Asian operating teams.